Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for the Treatment of Disinhibition in Patients With Neurodegenerative Disorders
NCT02534038Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deudextromethorphan in disinhibition, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Dec 2015; status: terminated.
02
Drugs
deudextromethorphan
03
Conditions
disinhibition
Beyond the preview
Go deeper on NCT02534038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534038.